Linking Pneumocystis jiroveci sulfamethoxazole resistance to the alleles of the DHPS gene using functional complementation in Saccharomyces cerevisiae

Curative and prophylactic therapy for Pneumocystis jiroveci pneumonia relies mainly on co-trimoxazole, an association of trimethoprim and sulfamethoxazole (SMX). SMX inhibits the folic acid pathway through competition with para-aminobenzoic acid (pABA), one of the two substrates of the dihydropteroa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical microbiology and infection 2010-05, Vol.16 (5), p.501-507
Hauptverfasser:	Moukhlis, R., Boyer, J., Lacube, P., Bolognini, J., Roux, P., Hennequin, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antifungal Agents - pharmacology co-trimoxazole Competition Complementation Cotrimoxazole DHPS gene Dihydropteroate synthase Dihydropteroate Synthase - genetics Drug Resistance, Fungal Enzymes Folic acid Genes, Fungal Genetic Complementation Test - methods Humans Microbial Sensitivity Tests para-aminobenzoic acid Plasmids Pneumocystis Pneumocystis carinii - drug effects Pneumocystis carinii - enzymology Pneumocystis carinii - genetics Pneumocystis jiroveci pneumocystosis Pneumonia Pneumonia, Pneumocystis - microbiology Point mutation Prophylaxis resistance Saccharomyces cerevisiae Saccharomyces cerevisiae - drug effects Saccharomyces cerevisiae - genetics Single-nucleotide polymorphism Sulfamethoxazole Sulfamethoxazole - pharmacology Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!